OABI at a glance
OmniAb, Inc. (OABI, SEC CIK 1846253) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and Form 4 insider filings as recently as August 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), OmniAb, Inc. (OABI) reported revenue of $18.7 million (down 29.3% from FY2024) and a net loss of $64.8 million. Diluted EPS was -$0.57.
- As of June 30, 2026, 24 institutional investment managers tracked by SignalX reported holding OmniAb, Inc. (OABI) shares worth $55.2 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $18.7M
- −29.3% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 24 funds
- $55.2M · +0 vs prior quarter
- Latest 8-K
- Aug 6, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Q2 revenue $13.415M, up 244% YoY from $3.897M
- License and milestone revenue strongest, $9.515M vs $1.242M YoY
- Net loss $5.859M vs $15.875M; effective tax rate 5.7% vs (0.8)%
- Cash, equivalents and short-term investments $52.0M; operating cash use $2.235M vs $21.018M
- Cash runway through at least next 12 months; tariffs, geopolitics and lower platform demand potential headwinds
Risk Factors
- No risk-factors section provided; supplied text contains Items 2–6 and signatures only
- No newly added risk factor identifiable from the provided filing text
- New change-in-control severance agreement effective July 13, 2026, involving Amechi Nwachuku
AI summary of the OABI 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 and six-month financial results for periods ended June 30, 2026, announced August 6, 2026
- Detailed results and management commentary contained in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 revenue $13.4M vs $3.9M, driven primarily by milestone revenue; first-half revenue reached $27.8M
- Net loss narrowed to $5.9M, or $0.05 per share, from $15.9M, or $0.15, year over year
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Amechi Nwachuku appointed COO effective July 13, 2026, adding senior commercial leadership across life sciences and diagnostics
- Initial base salary $445,000, with 45% target annual bonus and $20,000 signing bonus
Item 5.07: Submission of Matters to a Vote of Security Holders
- Jennifer Cochran and Matthew W. Foehr elected as Class I directors through 2029
- Foehr received 82,231,849 votes, while Cochran received 57,948,696
AI summaries of OABI 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for OABI
Don't miss the next OABI filing
- Alerts as it files. A push when OABI files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut OABI, by share count.
- Ask anything. An AI agent that reads every OABI filing and answers with sources.
OABI alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Nwachuku Amechi Ekeke | A | Aug 1, 2026 | 800,000 | - |
| Crouse Steven C. | A | Jun 17, 2026 | 40,000 | - |
| Cochran Jennifer R. | M | Jun 17, 2026 | 20,000 | - |
| Gotwals Philip J | M | Jun 17, 2026 | 20,000 | - |
| Cochran Jennifer R. | M | Jun 17, 2026 | 20,000 | - |
| Crouse Steven C. | A | Jun 17, 2026 | 20,000 | - |
| Gotwals Philip J | M | Jun 17, 2026 | 20,000 | - |
| Crouse Steven C. | M | Jun 17, 2026 | 20,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $26.4M | $18.7M |
| Operating Income | - | -$74.5M | -$69.0M |
| Net Income | -$50.6M | -$62.0M | -$64.8M |
| Op. Margin | - | -282.3% | -369.5% |
| Net Margin | - | -235.1% | -347.0% |
| Balance Sheet | |||
| Total Assets | - | $325.6M | $300.9M |
| Equity | $314.6M | $287.6M | $267.0M |
| ROE | -16.1% | -21.6% | -24.3% |
| Per Share | |||
| EPS | $-0.51 | $-0.61 | $-0.57 |
| Cash Flow | |||
| Operating CF | - | -$39.7M | -$36.5M |
| CapEx | $1.6M | $1.9M | $565K |
Source: XBRL data in OmniAb, Inc. (OABI)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate OABI share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 24 | $55.2M |
| Q1 2026 | 24 | $33.6M |
| Q4 2025 | 22 | $42.2M |
| Q3 2025 | 24 | $37.7M |
| Q2 2025 | 25 | $42.8M |
| Q1 2025 | 18 | $33.1M |
| Q4 2024 | 14 | $43.2M |
| Q3 2024 | 12 | $27.8M |
- BlackRock+790.6K (+10%)
- Renaissance Technologies LLC+330.8K (+123%)
- D.E. Shaw & Co+179.2K (+47%)
- Two Sigma Investments+144.7K (+28%)
- Vanguard Portfolio Management LLC+76.6K (+8%)
- Dimensional Fund Advisors−483.1K (-28%)
- Citadel Advisors LLC−170.5K (-75%)
- Vanguard Capital Management LLC−141.3K (-4%)
- Millennium Management−49.8K (-9%)
- Morgan Stanley−36.4K (-9%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 163 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
OABI filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Aug 3, 2026 | - | - | - |
| 8-K | Jul 13, 2026 | - | Analysis | - |
| 4 | Jun 18, 2026 | - | - | - |
| 8-K | Jun 18, 2026 | - | Analysis | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 4 | Apr 21, 2026 | - | - | - |
| 4 | Apr 21, 2026 | - | - | - |
| 4 | Apr 7, 2026 | - | - | - |
| 4 | Apr 7, 2026 | - | - | - |
| 4 | Apr 7, 2026 | - | - | - |
| 10-K | Mar 4, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 4, 2026 | - | Analysis | - |
| 4 | Feb 18, 2026 | - | - | |
| 4 | Feb 17, 2026 | - | - | |
| 4 | Feb 17, 2026 | - | - | |
| 4 | Feb 17, 2026 | - | - | |
| 8-K | Jan 30, 2026 | - | - |
Related Health Care companies
- ABSI · Absci CorpServices-Commercial Physical & Biological Research
- CRL · Charles River LaboratoriesServices-Commercial Physical & Biological Research
- INCY · IncyteServices-Commercial Physical & Biological Research
- IQV · IQVIAServices-Commercial Physical & Biological Research
- MXCT · MAXCYTE, INC.Services-Commercial Physical & Biological Research
- NRC · NATIONAL RESEARCH CORPServices-Commercial Physical & Biological Research
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
OABI SEC filings: frequently asked questions
Which institutions hold OABI stock?
As of June 30, 2026, the largest OmniAb, Inc. (OABI) holders among the 13F filers tracked by SignalX were BlackRock ($21.9 million), Vanguard Capital Management LLC ($9.5 million), State Street Corp ($5.2 million), Dimensional Fund Advisors ($3.1 million), Vanguard Portfolio Management LLC ($2.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was OABI's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), OmniAb, Inc. (OABI) reported revenue of $18.7 million (down 29.3% from FY2024) and a net loss of $64.8 million. Diluted EPS was -$0.57. The figures come from the XBRL data in the 10-K.
What did OABI report in its latest 8-K?
OmniAb, Inc. (OABI) filed an 8-K on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 and six-month financial results for periods ended June 30, 2026, announced August 6, 2026.
What are the latest OABI SEC filings?
OmniAb, Inc. (OABI) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and a Form 4 insider filing on August 3, 2026.
What is OABI's SEC CIK number?
OmniAb, Inc. (OABI)'s SEC Central Index Key (CIK) is 1846253. EDGAR lists every OABI filing under that number.
Ask anything about OABI
The research agent reads OABI's filings, financials, insider trades and 13F holders, then answers with sources.